Preclinical screening for cardiovascular disease with high-sensitivity cardiac troponins: ready, set, go?

While there may be significant public health policy interest in defining preclinical disease using hs-cTn assays, widespread adoption of a clinical screening program will become possible only if a cost-effective and safe intervention is readily available. 2.

also in 13,097 other papers